An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Walgreens Boots Alliance (WBA) has sold shares of Cencora, Inc. (COR) for $992 million, with $942 million sold pursuant to Rule 144 and a concurrent share repurchase by Cencora of approximately $50 million. The proceeds will be used for debt paydown and general corporate purposes, with no impact on the ongoing collaboration and long-term strategic partnership between the two companies.
Positive
None.
Negative
None.
Transaction Highlights
Walgreens Boots Alliance announces sale of shares of Cencora, Inc. for proceeds of $992 million
Approximately $942 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora of approximately $50 million
Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes
No change to ongoing collaboration and long-term strategic partnership
DEERFIELD, Ill.--(BUSINESS WIRE)--
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million.
Walgreens Boots Alliance’s ownership of Cencora’s common stock has decreased from approximately 15 percent to approximately 13 percent.
Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes, as the company continues to build out a more capital-efficient health services strategy rooted in its retail pharmacy footprint.
The sale has no impact to the long-term partnership between the two companies. Walgreens Boots Alliance remains fully committed to the strategic, mutually beneficial relationship with Cencora, which has been a strong and trusted partner since 2013. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on Cencora’s Board of Directors.
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities.
A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. The Company is reimagining local healthcare and well-being for all as part of its purpose – to create more joyful lives through better health. Through dispensing medicines, improving access to a wide range of health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare.
WBA employs more than 330,000 people and has a presence in eight countries through its portfolio of consumer brands: Walgreens, Boots, Duane Reade, the No7 Beauty Company and Benavides in Mexico. Additionally, WBA has a portfolio of healthcare-focused investments located in several countries, including China and the U.S.
The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA has been recognized for its commitment to operating sustainably: the Company is an index component of the Dow Jones Sustainability Indices (DJSI) and was named to the 100 Best Corporate Citizens 2022.
amerisourcebergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain and enhance patient care. as the leader in global sourcing and distribution, we source and distribute brand, generic, specialty, otc pharmaceuticals and other healthcare products. we increase the effectiveness and efficiency of your supply chain by ensuring products are delivered securely, consistently and cost-effectively, improving product access for pharmacies, providers and patients. our pharmacy solutions result in greater operational efficiency, cost control, growth opportunities and patient safety. our provider solutions drive operational efficiency, financial performance and improve quality of care. our manufacturer solutions maximize success at every stage of the product lifecycle. amerisourcebergen. where knowledge, reach and partnership shape healthcare delivery.